A population-based case-cohort study of breast cancer-specific survival among all first invasive breast cancer cases
Study Type
OBSERVATIONAL
Enrollment
3,000
chemotherapy/endocrine therapy/surgery/radiotherapy
Evgeny Pokushalov
Novosibirsk, Russia
RECRUITINGThe percentage of guideline-consistent and personalized EBM recommendations
The percentage of guideline-consistent and personalized EBM recommendations acted on by clinicians in patients with first invasive breast cancer. All discrepancies between routine and CDSS-recommended treatment resulting in frame of guideline-consistent therapy and personalized EBM therapy will be adjudicated by core laboratory.
Time frame: 3-year
Breast cancer-specific survival
All deaths due to breast cancer-related causes
Time frame: 3-year
Quantify the performance of the CDSS (MedicBK) algorithm
Quantify the performance of the CDSS (MedicBK) algorithm for presents treatment suggestions in frame of guideline-based therapy and personalized EBM therapy: the sensitivity, specificity, NPV, and PPV
Time frame: 3-year
Predictors
Predictors of guideline-consistent and personalized EBM adherence
Time frame: 3-year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.